CAJ | 학술논문

目的：探讨紫杉醇脂质体与顺铂周疗方案同步放疗治疗中晚期宫颈癌的临床疗效。方法抽取2013年9月~2014年9月于我院就诊的中晚期宫颈癌患者共86例，随机分为实验组与对照组，实验组（n=43）予以紫杉醇脂质体周疗（90 mg·m-2）联合放疗，共4～6周。对照组（n=43）予以顺铂周疗（40 mg·m-2）联合放疗，共4～6周。观察和比较两组患者的治疗效果和不良反应的发生情况。结果实验组治疗总有效率为90.1％，对照组为93.0％，两组比较差异无统计学意义（P>0.05）；实验组白细胞减少、血小板降低、恶心呕吐和脱发的发生率较对照组显著降低（P<0.05），但两组腹泻和肝肾损害的发生率比较，差异无统计学意义（P>0.05）。结论紫杉醇脂质体与顺铂周疗方案同步放化疗治疗中晚期宫颈癌的临床效果相当，但紫杉醇脂质体周疗同步放化疗的安全性更高。
목적：탐토자삼순지질체여순박주료방안동보방료치료중만기궁경암적림상료효。방법추취2013년9월~2014년9월우아원취진적중만기궁경암환자공86례，수궤분위실험조여대조조，실험조（n=43）여이자삼순지질체주료（90 mg·m-2）연합방료，공4～6주。대조조（n=43）여이순박주료（40 mg·m-2）연합방료，공4～6주。관찰화비교량조환자적치료효과화불량반응적발생정황。결과실험조치료총유효솔위90.1％，대조조위93.0％，량조비교차이무통계학의의（P>0.05）；실험조백세포감소、혈소판강저、악심구토화탈발적발생솔교대조조현저강저（P<0.05），단량조복사화간신손해적발생솔비교，차이무통계학의의（P>0.05）。결론자삼순지질체여순박주료방안동보방화료치료중만기궁경암적림상효과상당，단자삼순지질체주료동보방화료적안전성경고。
Objective To investigate the clinical efficacy and safety of weekly paclitaxel liposome and cisplatin chemo-therapy plus concurrent radiotherapy in the treatment of middle and advanced cervical cancer. Methods From September 2013 to September 2014, 86 patients with middle and advanced cervical cancer who received concurrent chemoradiotherapy in our hospital were selected. All cases were divided into experimental group and control group according to different chemotherapy regimens during radiation therapy. Patients in experimental group (n=43) received radiotherapy concomitant with weekly pacli-taxel liposome (90 mg·m-2) for 4-6 weeks, while those in control group (n=43) received radiotherapy concomitant with cisplatin (90 mg·m-2) for 4-6 weeks. The clinical efficacy and incidence of adverse reactions were observed and compared between two groups. Results The effective rates were respectively 90.1% and 93% in experimental group and control group, and there was no significant difference (P>0.05). The incidence of leucopenia, nausea & vomit, thrombocytopenia and calvities in experimental group were significantly higher than those in the control group (P<0.05). However, no significant differences were found in the occurrence rates of diarrhea and liver and renal dysfunction between two groups (P>0.05). Conclusions The weekly paclitaxel liposome plus concurrent radiotherapy had equal efficacy to but higher safety than the weekly cisplatin plus concurrent radio-therapy in the treatment of middle and advanced cervical cancer.